Merck-Moderna Cancer Vaccine Breakthrough Sends Shares Skyrocketing

The Merck and Moderna mRNA-based cancer vaccine, intismeran autogene, has shown positive Phase III results, making it a significant breakthrough in cancer therapy.

Shares of Merck and Moderna skyrocketed after the announcement, with Merck's stock increasing 10% and Moderna's shares surging 177%, adding $45 billion to its market capitalization.

The vaccine works by targeting individual genetic mutations in each patient's tumor, making it a highly personalized therapy.

Sequencing companies such as Illumina, Pacific Biosciences of California, and Oxford Nanopore Technologies also saw their shares jump due to the increased demand for sequencing technologies in cancer treatment.

Analysts are optimistic about Moderna's future prospects, with some predicting that the company will significantly broaden its sales beyond its COVID-19 vaccines.

However, not all analysts share this enthusiasm, with Daina M. Graybosch, PhD, of Leerink Partners cautioning that expectations may be overly optimistic and difficult to meet.